Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Stem Cells in Heart Failure
NCT03227198Phase 2Unknown
- Sponsor
- SCARM Institute
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in heart failure (HF) (2 arms), sponsored by SCARM Institute. Primary endpoints: Death at 12 months and Hospitalization at 12 months. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03227198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227198.